title: Vasoactive intestinal peptide impairs leucocyte migration but fails to modify experimental murine colitis.
abstract: Inflammatory bowel diseases are chronic inflammatory disorders of the gastrointestinal tract. Vasoactive intestinal peptide (VIP) is a neuropeptide with known anti-inflammatory activity. We have demonstrated previously that administration of VIP inhibits leucocyte migration in a murine model of delayed-type hypersensitivity, and anti-inflammatory efficacy is supported by other studies. The aim of this study was to investigate the VIP effects in a murine model of intestinal inflammation. Colitis was induced in BALB/c mice by a 2.5 mg enema of 2,4,6-trinitrobenzenesulphonic acid (TNBS) and the mice were killed on day 7. Mice were administered either a 3-day (therapeutic) or 7-day (prophylactic) constant infusion of VIP by subcutaneously implanted mini-osmotic pumps, or intraperitoneal (i.p.) injection of VIP on alternate days over 7 days. Clinical disease scores, weight changes, histopathology of colon tissues, plasma VIP levels, cytokine levels and chemotaxis of peripheral blood mononuclear cells were evaluated. After administration of TNBS, mice quickly developed severe colitis accompanied by dramatic body weight loss (20% by day 6) and high mortality (30%). Prophylactic treatment using high-dose VIP abrogated leucocyte chemotaxis; however, it failed to ameliorate the weight loss and mortality. Moreover, VIP delivered either by constant infusion or i.p. failed to modify the clinical, histological or cytokine markers of disease. Our studies show that, despite an ability to inhibit chemokine-induced chemotaxis of mononuclear cells, VIP was unable to modulate TNBS-induced colitis. This contrasts with the efficacy of VIP in models of mild inflammatory disease and suggests that VIP is unlikely to provide a useful model for novel anti-IBD therapy.
authors.affiliation: Department of Medicine, St George Clinical School, Kogarah, NSW, Australia.
authors.forename: R
authors.initials: R
authors.lastname: Newman
authors.forename: N
authors.initials: N
authors.lastname: Cuan
authors.forename: T
authors.initials: T
authors.lastname: Hampartzoumian
authors.forename: S J
authors.initials: SJ
authors.lastname: Connor
authors.forename: A R
authors.initials: AR
authors.lastname: Lloyd
authors.forename: M C
authors.initials: MC
authors.lastname: Grimm
mesh_terms: D000208:Acute Disease; D000818:Animals; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D003092:Colitis / Q000188:drug therapy* / Q000276:immunology*; D015918:Infusion Pumps, Implantable; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D023421:Models, Animal; D017211:Treatment Failure; D014302:Trinitrobenzenesulfonic Acid; D014660:Vasoactive Intestinal Peptide / Q000627:therapeutic use*
chemical_list: D014660:Vasoactive Intestinal Peptide; D014302:Trinitrobenzenesulfonic Acid
references.citation: Nat Med. 2002 Jun;8(6):567-73
references.pmid: 12042806
references.citation: J Clin Invest. 2003 May;111(9):1329-38
references.pmid: 12727924
references.citation: J Gastroenterol. 2003 Mar;38 Suppl 15:36-42
references.pmid: 12698869
references.citation: Arch Physiol Biochem. 2002 Apr;110(1-2):74-89
references.pmid: 11935403
references.citation: Int J Colorectal Dis. 2000 Jun;15(3):144-60
references.pmid: 10954186
references.citation: J Immunol. 1999 Jan 15;162(2):1200-5
references.pmid: 9916753
references.citation: J Neuroimmunol. 1999 Sep 1;99(1):61-71
references.pmid: 10496178
references.citation: Gastroenterology. 2002 Dec;123(6):1912-22
references.pmid: 12454848
references.citation: Lancet. 2002 Jan 5;359(9300):62-9
references.pmid: 11809204
references.citation: J Exp Med. 2000 Jul 3;192(1):41-52
references.pmid: 10880525
references.citation: J Mol Med (Berl). 2002 Jan;80(1):16-24
references.pmid: 11862320
references.citation: Eur J Immunol. 1997 Jul;27(7):1743-50
references.pmid: 9247586
references.citation: Gastroenterology. 1999 Nov;117(5):1078-88
references.pmid: 10535870
references.citation: J Clin Invest. 1997 Dec 1;100(11):2766-76
references.pmid: 9389741
references.citation: Lancet. 1973 Jul 7;2(7819):14-6
references.pmid: 4123289
references.citation: Expert Opin Pharmacother. 2000 May;1(4):615-22
references.pmid: 11249506
references.citation: Gut. 1997 Oct;41(4):487-93
references.pmid: 9391247
references.citation: J Leukoc Biol. 2000 Mar;67(3):267-78
references.pmid: 10733087
references.citation: J Exp Med. 1999 Apr 19;189(8):1169-80
references.pmid: 10209035
references.citation: Annu Rev Immunol. 2002;20:495-549
references.pmid: 11861611
references.citation: Curr Pharm Des. 2001 Jan;7(2):89-111
references.pmid: 11172702
references.citation: Arthritis Rheum. 2002 Jan;46(1):271-3
references.pmid: 11817602
references.citation: J Exp Med. 2001 Apr 2;193(7):827-38
references.pmid: 11283155
references.citation: J Exp Med. 1995 Nov 1;182(5):1281-90
references.pmid: 7595199
references.citation: Dig Dis Sci. 1996 Aug;41(8):1625-30
references.pmid: 8769290
references.citation: J Immunol. 1996 Aug 1;157(3):1261-70
references.pmid: 8757634
references.citation: World J Surg. 1998 Apr;22(4):382-9
references.pmid: 9523521
references.citation: Gastroenterology. 2003 Apr;124(4):961-71
references.pmid: 12671893
references.citation: Agents Actions. 1992;Spec No:C15-7
references.pmid: 1359742
references.citation: Dig Dis Sci. 1998 Nov;43(11):2518-25
references.pmid: 9824145
references.citation: Clin Exp Pharmacol Physiol. 1992 Oct;19(10):717-22
references.pmid: 1424301
references.citation: J Immunol Methods. 2003 Feb;273(1-2):3-13
references.pmid: 12535793
references.citation: J Exp Med. 1998 Jul 20;188(2):317-25
references.pmid: 9670044
references.citation: J Immunol. 1998 Aug 1;161(3):1069-73
references.pmid: 9686562
references.citation: J Immunol. 2003 Nov 15;171(10):4990-4
references.pmid: 14607894
references.citation: Gastroenterology. 1999 Oct;117(4):866-76
references.pmid: 10500069
references.citation: Gastroenterology. 1989 Mar;96(3):795-803
references.pmid: 2914642
references.citation: Front Neuroendocrinol. 1995 Jan;16(1):53-88
references.pmid: 7768322
references.citation: Curr Opin Immunol. 1999 Dec;11(6):648-56
references.pmid: 10631550
references.citation: Immunol Today. 2000 Jan;21(1):7-11
references.pmid: 10637552
references.citation: Am J Pathol. 1997 Mar;150(3):823-32
references.pmid: 9060820
references.citation: Trends Endocrinol Metab. 1991 May-Jun;2(3):107-12
references.pmid: 18411175
references.citation: Clin Exp Immunol. 1995 Aug;101(2):351-6
references.pmid: 7648720
references.citation: Trends Mol Med. 2003 May;9(5):218-22
references.pmid: 12763527
references.citation: Ann N Y Acad Sci. 1988;527:1-19
references.pmid: 3133967
references.citation: J Immunol. 1999 Oct 15;163(8):4213-23
references.pmid: 10510358
references.citation: J Immunol. 2001 Mar 1;166(5):2907-12
references.pmid: 11207237